Ventricular assist device in severe heart failure: Effects on cytokines, complement and body weight

A. L. Clark, Matthias Loebe, E. V. Potapov, K. Egerer, C. Knosalla, R. Hetzer, S. D. Anker

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Aims: Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities. Methods: We studied 48 patients (39 males; age 2 45±2 years) with NYHA class IV heart failure. All patients underwent ventricular assist device implantation for endstage heart failure as a bridge to cardiac transplantation. Plasma levels of tumour necrosis factor α, and its receptors, interleukin-6, elastase, activated complement, and soluble CD14 receptors were measured at the time of operation and in survivors at 1 week (n=46), 40 days (n=35) and 90 days (n=26). Follow-up was for a minimum of 1 year. Results: One-year survival was 35% (95% CI: 22-49%). Body mass index was the only predictor of survival (body mass index >25 (n=16); survival 63 (39-86) %; body mass index <25 (n=32); survival 22 (7·5-36)%: P=0·003). Tumour necrosis factor α fell from 9·66 ± 1·33 pg. ml-1 to 4·2 ± 1·0 at 1 week (P=0·008), but returned to preoperative levels at 90 days. Interleukin-6, activated complement and elastase fell progressively to 40 days, but were rising at 90 days. There was no change in tumour necrosis factor receptor. There was a gradual rise in CD14 (3·99 ± 0·15 μg. ml-1 at baseline, 5·02 ± 0·39 at 90 days, P=0·006). After surgery, body weight fell from 80 ± 2 to 73 ± 2kg by 1 month (P<0·001) and to 72 ± 2kg at 90 days. Conclusions: Ventricular assist device implantation results in a short-term fall in tumour necrosis factor α and interleukin-6, but no change in CD14 or tumour necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist device implantation. Low body mass index is related to poor outcome after assist device implantation, and no weight gain.

Original languageEnglish (US)
Pages (from-to)2275-2283
Number of pages9
JournalEuropean Heart Journal
Volume22
Issue number24
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Heart-Assist Devices
Tumor Necrosis Factor Receptors
Body Mass Index
Heart Failure
Body Weight
Cytokines
Interleukin-6
Survival
Pancreatic Elastase
Tumor Necrosis Factor-alpha
Equipment and Supplies
Heart Transplantation
Cardiac Output
Weight Gain
Survivors
Inflammation

Keywords

  • Chronic heart failure
  • Cytokines
  • Tumour necrosis factor α
  • Ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clark, A. L., Loebe, M., Potapov, E. V., Egerer, K., Knosalla, C., Hetzer, R., & Anker, S. D. (2001). Ventricular assist device in severe heart failure: Effects on cytokines, complement and body weight. European Heart Journal, 22(24), 2275-2283. https://doi.org/10.1053/euhj.2001.2693

Ventricular assist device in severe heart failure : Effects on cytokines, complement and body weight. / Clark, A. L.; Loebe, Matthias; Potapov, E. V.; Egerer, K.; Knosalla, C.; Hetzer, R.; Anker, S. D.

In: European Heart Journal, Vol. 22, No. 24, 2001, p. 2275-2283.

Research output: Contribution to journalArticle

Clark, AL, Loebe, M, Potapov, EV, Egerer, K, Knosalla, C, Hetzer, R & Anker, SD 2001, 'Ventricular assist device in severe heart failure: Effects on cytokines, complement and body weight', European Heart Journal, vol. 22, no. 24, pp. 2275-2283. https://doi.org/10.1053/euhj.2001.2693
Clark, A. L. ; Loebe, Matthias ; Potapov, E. V. ; Egerer, K. ; Knosalla, C. ; Hetzer, R. ; Anker, S. D. / Ventricular assist device in severe heart failure : Effects on cytokines, complement and body weight. In: European Heart Journal. 2001 ; Vol. 22, No. 24. pp. 2275-2283.
@article{00a6699e754f4684bec18ccc9d952b06,
title = "Ventricular assist device in severe heart failure: Effects on cytokines, complement and body weight",
abstract = "Aims: Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities. Methods: We studied 48 patients (39 males; age 2 45±2 years) with NYHA class IV heart failure. All patients underwent ventricular assist device implantation for endstage heart failure as a bridge to cardiac transplantation. Plasma levels of tumour necrosis factor α, and its receptors, interleukin-6, elastase, activated complement, and soluble CD14 receptors were measured at the time of operation and in survivors at 1 week (n=46), 40 days (n=35) and 90 days (n=26). Follow-up was for a minimum of 1 year. Results: One-year survival was 35{\%} (95{\%} CI: 22-49{\%}). Body mass index was the only predictor of survival (body mass index >25 (n=16); survival 63 (39-86) {\%}; body mass index <25 (n=32); survival 22 (7·5-36){\%}: P=0·003). Tumour necrosis factor α fell from 9·66 ± 1·33 pg. ml-1 to 4·2 ± 1·0 at 1 week (P=0·008), but returned to preoperative levels at 90 days. Interleukin-6, activated complement and elastase fell progressively to 40 days, but were rising at 90 days. There was no change in tumour necrosis factor receptor. There was a gradual rise in CD14 (3·99 ± 0·15 μg. ml-1 at baseline, 5·02 ± 0·39 at 90 days, P=0·006). After surgery, body weight fell from 80 ± 2 to 73 ± 2kg by 1 month (P<0·001) and to 72 ± 2kg at 90 days. Conclusions: Ventricular assist device implantation results in a short-term fall in tumour necrosis factor α and interleukin-6, but no change in CD14 or tumour necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist device implantation. Low body mass index is related to poor outcome after assist device implantation, and no weight gain.",
keywords = "Chronic heart failure, Cytokines, Tumour necrosis factor α, Ventricular assist device",
author = "Clark, {A. L.} and Matthias Loebe and Potapov, {E. V.} and K. Egerer and C. Knosalla and R. Hetzer and Anker, {S. D.}",
year = "2001",
doi = "10.1053/euhj.2001.2693",
language = "English (US)",
volume = "22",
pages = "2275--2283",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Ventricular assist device in severe heart failure

T2 - Effects on cytokines, complement and body weight

AU - Clark, A. L.

AU - Loebe, Matthias

AU - Potapov, E. V.

AU - Egerer, K.

AU - Knosalla, C.

AU - Hetzer, R.

AU - Anker, S. D.

PY - 2001

Y1 - 2001

N2 - Aims: Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities. Methods: We studied 48 patients (39 males; age 2 45±2 years) with NYHA class IV heart failure. All patients underwent ventricular assist device implantation for endstage heart failure as a bridge to cardiac transplantation. Plasma levels of tumour necrosis factor α, and its receptors, interleukin-6, elastase, activated complement, and soluble CD14 receptors were measured at the time of operation and in survivors at 1 week (n=46), 40 days (n=35) and 90 days (n=26). Follow-up was for a minimum of 1 year. Results: One-year survival was 35% (95% CI: 22-49%). Body mass index was the only predictor of survival (body mass index >25 (n=16); survival 63 (39-86) %; body mass index <25 (n=32); survival 22 (7·5-36)%: P=0·003). Tumour necrosis factor α fell from 9·66 ± 1·33 pg. ml-1 to 4·2 ± 1·0 at 1 week (P=0·008), but returned to preoperative levels at 90 days. Interleukin-6, activated complement and elastase fell progressively to 40 days, but were rising at 90 days. There was no change in tumour necrosis factor receptor. There was a gradual rise in CD14 (3·99 ± 0·15 μg. ml-1 at baseline, 5·02 ± 0·39 at 90 days, P=0·006). After surgery, body weight fell from 80 ± 2 to 73 ± 2kg by 1 month (P<0·001) and to 72 ± 2kg at 90 days. Conclusions: Ventricular assist device implantation results in a short-term fall in tumour necrosis factor α and interleukin-6, but no change in CD14 or tumour necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist device implantation. Low body mass index is related to poor outcome after assist device implantation, and no weight gain.

AB - Aims: Inflammatory and immune activation and body wasting are important features of end-stage chronic heart failure. It is not known whether restoration of cardiac output by assist device implantation can improve these abnormalities. Methods: We studied 48 patients (39 males; age 2 45±2 years) with NYHA class IV heart failure. All patients underwent ventricular assist device implantation for endstage heart failure as a bridge to cardiac transplantation. Plasma levels of tumour necrosis factor α, and its receptors, interleukin-6, elastase, activated complement, and soluble CD14 receptors were measured at the time of operation and in survivors at 1 week (n=46), 40 days (n=35) and 90 days (n=26). Follow-up was for a minimum of 1 year. Results: One-year survival was 35% (95% CI: 22-49%). Body mass index was the only predictor of survival (body mass index >25 (n=16); survival 63 (39-86) %; body mass index <25 (n=32); survival 22 (7·5-36)%: P=0·003). Tumour necrosis factor α fell from 9·66 ± 1·33 pg. ml-1 to 4·2 ± 1·0 at 1 week (P=0·008), but returned to preoperative levels at 90 days. Interleukin-6, activated complement and elastase fell progressively to 40 days, but were rising at 90 days. There was no change in tumour necrosis factor receptor. There was a gradual rise in CD14 (3·99 ± 0·15 μg. ml-1 at baseline, 5·02 ± 0·39 at 90 days, P=0·006). After surgery, body weight fell from 80 ± 2 to 73 ± 2kg by 1 month (P<0·001) and to 72 ± 2kg at 90 days. Conclusions: Ventricular assist device implantation results in a short-term fall in tumour necrosis factor α and interleukin-6, but no change in CD14 or tumour necrosis factor receptor, suggesting that the pathophysiological process resulting in inflammation was not altered by left ventricular assist device implantation. Low body mass index is related to poor outcome after assist device implantation, and no weight gain.

KW - Chronic heart failure

KW - Cytokines

KW - Tumour necrosis factor α

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=0035658141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035658141&partnerID=8YFLogxK

U2 - 10.1053/euhj.2001.2693

DO - 10.1053/euhj.2001.2693

M3 - Article

C2 - 11728148

AN - SCOPUS:0035658141

VL - 22

SP - 2275

EP - 2283

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 24

ER -